Related Experiment Video
Updated: May 5, 2026
08:31
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
4.8K
Beyond contracts: principles for Pharma-CRO collaboration from the European Bioanalysis Forum.
Philip Timmerman1, Matthew Barfield2, Lee Goodwin3
1European Bioanalysis Forum, Brussels, Belgium.
Bioanalysis
|November 6, 2025
Summary
Effective collaboration between pharmaceutical companies and contract research organizations is key for drug development. This study outlines essential principles for reliable partnerships, improving communication and project outcomes for patient benefit.
Area of Science:
- Drug Development
- Pharmaceutical Industry
- Contract Research Organizations
Background:
- Pharmaceutical development relies heavily on collaborations between sponsors and contract research organizations (CROs).
- Common challenges include poor communication, unclear expectations, transactional relationships, and functional silos, hindering project success.
- Addressing these weaknesses is crucial for efficient drug development.
Purpose of the Study:
- To identify and propose principles for enhancing collaboration between pharmaceutical companies and CROs.
- To improve communication strategies tailored to different project phases.
- To foster sustainable, long-term partnerships beyond mere transactions.
Main Methods:
- Analysis of collaboration issues by dedicated teams within the European Bioanalysis Forum.
- Focus on communication strategies and building sustainable partnerships.
- Validation and refinement of principles through community dialogue at a Focus Workshop and leadership input.
Main Results:
- Identification of key principles essential for reliable collaboration in drug development.
- Emphasis on adaptive communication and clear expectation setting.
- Framework for moving from transactional relationships to sustainable partnerships.
Conclusions:
- Implementing structured principles can significantly improve the reliability of pharmaceutical-CRO collaborations.
- Enhanced collaboration accelerates scientific progress and benefits patients.
- The proposed principles serve as a foundation for optimizing partnership dynamics.
Related Concept Videos
01:28Biopharmaceutics and Pharmacokinetics: Overview
4.7K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
4.7K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
631
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
631
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
252
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
252
01:13Bioequivalence studies: Biowaivers
433
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
433
01:28Drug Products: Biologics, Biosimilars and Interchangeables
370
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
370
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
561
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
561